Abstract
Coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) are proven effective treatments of coronary artery disease (CAD), however, the optimal revascularization strategy remains unclear in certain patient subsets. The recently published "Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)" trial is a randomized study evaluating the use of CABG vs PCI in diabetic patients with multivessel coronary disease. The purpose of this editorial is to review the FREEDOM trial and the available literature guiding clinicians to make evidence-based decisions when treating diabetic patients with multivessel coronary disease. The current evidence suggests that CABG should remain the standard of care for this patient population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
